{"product_id":"luye-business-model-canvas","title":"Luye Pharma Group Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLuye Pharma BMC Snapshot: R\u0026amp;D-led growth, partnerships \u0026amp; revenue streams\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eUnlock the strategic core of Luye Pharma Group with our concise Business Model Canvas preview—see how R\u0026amp;D-driven value propositions, key partnerships, and diversified revenue streams combine to fuel growth. Ideal for investors, consultants, and founders seeking a practical roadmap, the full downloadable Canvas (Word \u0026amp; Excel) delivers all nine building blocks, company-specific insights, and actionable takeaways to replicate or benchmark success.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Licensing Partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCollaborative licensing deals with global pharma firms enable Luye Pharma Group to commercialize oncology drug Rykindo in the US and EU by leveraging partners’ sales forces and local regulatory expertise; in 2024 Luye reported 18% international revenue growth, and such deals typically reduce commercialization capex by ~30% while sharing revenue splits often in the 60\/40 to 70\/30 range, accelerating market entry vs organic routes.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAcademic and Research Institutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLuye Pharma Group partners with top universities and medical centers worldwide to co-develop early-stage molecules, sharing discovery costs—Luye reported R\u0026amp;D spend of RMB 3.1 billion in 2024, lowering per-project risk. These alliances produced multiple 2023–2025 patents and accelerated hires: 120+ senior researchers joined R\u0026amp;D from academia between 2022–2024, feeding Luye’s therapeutic pipeline.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLocal Distribution and Logistics Networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDeep-rooted alliances with regional distributors in emerging markets (covering ~35% of Luye Pharma Group’s 2024 international sales of RMB 4.2 billion) push products beyond metro centers, reaching secondary cities and rural clinics.\u003c\/p\u003e\n\u003cp\u003eThese partners handle localized logistics and regulatory navigation, preserving cold-chain integrity for biologics—reducing transit-related spoilage from industry-average 8% to Luye’s reported ~3% on key shipments in 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eContract Research Organizations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eLuye Pharma partners with specialized contract research organizations to run multi-regional trials, outsourcing site management and monitoring to stay lean while meeting EMA\/FDA standards; in 2024 CRO-driven trials enabled a 40% faster enrollment and supported simultaneous Phase III programs across Asia, Europe, and North America.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eReduced fixed R\u0026amp;D headcount by ~25% in 2024\u003c\/li\u003e\n\u003cli\u003eAverage CRO contract for Phase III ~ $45–70M per program\u003c\/li\u003e\n\u003cli\u003eEnrollment acceleration: +40% vs in-house in 2024\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernment and Regulatory Agencies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eContinuous engagement with regulators such as China NMPA and US FDA speeds approvals and compliance; Luye reported 18 regulatory approvals across markets in 2024, aiding faster launches and 22% revenue growth in oncology products that year.\u003c\/p\u003e\n\u003cp\u003eStrong regulator ties support national reimbursement listings—Luye secured 6 provincial\/national reimbursements in China by 2024, which materially increased domestic unit volumes and reduced price erosion.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e18 approvals in 2024\u003c\/li\u003e\n\u003cli\u003e22% oncology revenue growth (2024)\u003c\/li\u003e\n\u003cli\u003e6 reimbursement listings (by 2024)\u003c\/li\u003e\n\u003cli\u003eTransparency boosts market entry speed\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePartners cut capex 30%, drive 18% intl sales, 40% faster trials—R\u0026amp;D RMB3.1B, 18 approvals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eKey partners—global pharma licensors, universities, regional distributors, CROs, and regulators—cut commercialization capex ~30%, boosted international sales 18% (2024), and sped trials +40% enrollment; R\u0026amp;D spend RMB 3.1B (2024) and 18 approvals (2024) underpin growth.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eIntl revenue growth\u003c\/td\u003e\n\u003ctd\u003e18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend\u003c\/td\u003e\n\u003ctd\u003eRMB 3.1B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulatory approvals\u003c\/td\u003e\n\u003ctd\u003e18\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise, pre-crafted Business Model Canvas for Luye Pharma Group outlining its nine BMC blocks—customer segments, value propositions, channels, customer relationships, revenue streams, key resources, key activities, key partners, and cost structure—reflecting its integrated R\u0026amp;D, manufacturing, and global commercialization strategy with investor-ready narrative and competitive analysis to support strategic decisions and funding discussions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eHigh-level view of Luye Pharma Group’s business model with editable cells to quickly pinpoint R\u0026amp;D, manufacturing, and market-access levers as pain-point relievers for portfolio, pipeline, and supply-chain bottlenecks.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvanced Formulation R\u0026amp;D\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLuye Pharma invests in advanced formulation R\u0026amp;D—microspheres, liposomes, transdermal patches—to boost CNS and oncology drug efficacy and patient adherence; R\u0026amp;D spend was CNY 1.23bn in 2024 (up 14% YoY), with formulation projects accounting for roughly 28% of pipeline activities and 6 clinical-stage formulation-enabled assets as of Dec 31, 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Clinical Development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eManaging global Phase I–III trials across Asia, Europe, and North America—covering 120+ sites and ~8,400 patients in 2024—is core to securing international approvals; it requires standardized data capture, continuous patient safety monitoring, and biostatistical analysis to meet FDA, EMA, and NMPA standards. Successful trials unlock commercialization of Luye Pharma Group’s pipeline, which held 45+ IND\/NDA-stage assets and drove 2024 R\u0026amp;D spend of RMB 1.1 billion.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh-Tech Manufacturing Operations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOperating GMP-compliant facilities, Luye Pharma runs precision production for complex biologics and small-molecule APIs, supporting 2024 revenues of RMB 14.2 billion and CapEx ~RMB 1.1 billion; specialized single-use bioreactors and automated fill-finish lines cut batch variability by ~18%. Continuous process improvements raised API yields by 12% in 2023–24, lowering cost of goods sold by an estimated 6% and improving gross margin.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Marketing and Sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpexecuting targeted promotional campaigns educates neurologists and oncologists on luye pharma group innovative cns oncology therapies driving clinical adoption aiming to capture leading share in specialty markets where top drugs reach annual sales of by the trained force must translate complex phase iii evidence hospital formulary decision-makers.\u003e\n\u003cp class=\"lst_crct\"\u003e\n\u003c\/p\u003e\u003cli\u003eFocus: CNS and oncology specialists\u003c\/li\u003e\n\u003cli\u003eGoal: accelerate formulary listing, boost uptake\u003c\/li\u003e\n\u003cli\u003eMetric: target 20–30% market share in lead segments\u003c\/li\u003e\n\u003cli\u003eSales: clinical-trained reps for specialist\/Hospital channels\u003c\/li\u003e\n\u003cli\u003eEvidence: leverage Phase III and real-world outcomes\u003c\/li\u003e\n\u003c\/pexecuting\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntellectual Property Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eLuye Pharma actively files and defends patents for new molecular entities and delivery technologies across major jurisdictions, securing exclusivity—helping prevent generic entry and preserving revenue streams that supported RMB 3.6 billion (2024) in product sales.\u003c\/p\u003e\n\u003cp\u003eRobust IP raises asset value in licensing talks; recent deals showed IP-backed valuations premia of 20–35%, boosting upfronts and milestones for global partners.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eGlobal patent families filed across US, EU, CN, JP\u003c\/li\u003e\n\u003cli\u003eRMB 3.6B 2024 product sales protected by patents\u003c\/li\u003e\n\u003cli\u003eIP valuation premium 20–35% in recent licensing deals\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLuye Pharma: R\u0026amp;D-led growth—CNY1.23bn R\u0026amp;D, 45+ assets, RMB14.2bn revenue\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLuye Pharma scales formulation R\u0026amp;D, global Phase I–III trials, GMP biologics\/API manufacturing, specialist sales, and IP filing—2024: R\u0026amp;D CNY 1.23bn, 45+ IND\/NDA assets, 120+ trial sites\/≈8,400 patients, revenue RMB 14.2bn, CapEx RMB 1.1bn, product sales RMB 3.6bn; IP deal premiums 20–35%.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend\u003c\/td\u003e\n\u003ctd\u003eCNY 1.23bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAssets\u003c\/td\u003e\n\u003ctd\u003e45+ IND\/NDA\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTrial sites\/patients\u003c\/td\u003e\n\u003ctd\u003e120+\/≈8,400\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003eRMB 14.2bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe preview shown is the actual Luye Pharma Group Business Model Canvas you’ll receive after purchase — not a mockup or sample — and it reflects the same structure, content, and formatting included in the final deliverable.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56749498532217,"sku":"luye-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/luye-business-model-canvas.png?v=1772214457","url":"https:\/\/matrixbcg.com\/products\/luye-business-model-canvas","provider":"MatrixBCG","version":"1.0","type":"link"}